Jonas Bergquist

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
faculty.utah.edu

Jonas Bergquist, MD, PhD, is a Full Chair Professor in Analytical Chemistry and Neurochemistry at the Department of Chemistry at Uppsala University.[1] He also has served as an Associate Professor of Clinical Neuroscience at the Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden. In 1999, he became a Researcher in Uppsala University, Uppsala, Sweden. In 2005, he was appointed the Chaired Professor of Analytical Chemistry and Neurochemistry, heading the Bergquist group at the Department of Chemistry, Biomedical Centre, Uppsala University. Since 2011, he is an Adjunct Professor of Pathology at the University of Utah, Salt Lake City, US, and since 2015, a Professor of Precision Medicine, Binzhou Medical University, Yantai, China.[2]

Research interests: various neurodegenerative diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); his research "involves methods to measure substances that can act as biomarkers for early diagnosis and contribute to the understanding of what initiates the disease process... [and] measure not only the individual substances but also seek patterns and monitor how they change during illness,... [the Bergquist group's] specialty is the analysis of cerebrospinal fluid and its chemical composition."[2]

Dr Bergquist leads the Open Medicine Foundation's center in Uppsala, Sweden.[3]

Long COVID[edit | edit source]

Professor Bergquist is principal investigator for the Open Medicine Foundation's COVID-19 and ME/CFS study, which was announced in May 2020.[4]

Working groups and committees[edit | edit source]

ME/CFS Collaborative Research Center at Stanford University[edit | edit source]

Member of the Working Group which offers their expertise and resources to the ME/CFS Collaborative Research Center at Stanford University.[5]

EUROMENE[edit | edit source]

Dr. Bergquist is a member of the Biomarkers Working Group of ME/CFS across Europe on behalf of the EUROMENE, a European Union COST Action CA15111 not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Member of the Biomarkers Working Group and Neurologic/Cognitive/CNS Imaging Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[7]

2017 Ramsay Award[edit | edit source]

A team comprised of Dr. Bergquist and Dr. Jonas Blomberg of Uppsala University and Dr. Carl-Gerhard Gottfries and Dr. Olof Zachrisson of the Gottfries Clinic were awarded a 2017 Ramsay Award grant from the Solve ME/CFS Initiative for research into biomarkers for initiation (infection) and metabolic derangement in ME/CFS.[8]

Talks and interviews[edit | edit source]

Notable studies[edit | edit source]

  • 2021, Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[11] - (Full text)
  • 2021, Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[12] - (Full text)
  • 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts[13] - (Full text)
  • 2011, Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome[14] - (Full Text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.01.1 "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019.
  2. 2.02.1 Johansson, Åke. "Jonas Bergquist - Uppsala University, Sweden". katalog.uu.se. Retrieved April 25, 2019.
  3. "Collaborative Center - Uppsala". Open Medicine Foundation. Retrieved August 15, 2020.
  4. Open Medicine Foundation (June 17, 2020). "COVID-19 and ME news flash from Uppsala". omf.org. Retrieved September 19, 2020.
  5. "OMF grants $1.2M to Ramp Up Collaborative Research Center at Stanford University". bos.etapestry.com. Retrieved April 25, 2019.
  6. "Action CA15111". COST. Retrieved April 25, 2019.
  7. "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
  8. "2017 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved April 25, 2019.
  9. "Invest in ME Research - IIMEC10 International ME Conference 2015". www.investinme.org. Retrieved May 11, 2021.
  10. UppTalk Weekly: With hope for the patients with ME, one of the worl'ds most debilitating illnesses., retrieved May 11, 2021
  11. Stanculescu, Dominic; Larsson, Lars; Bergquist, Jonas (2021). "Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Medicine. 8. doi:10.3389/fmed.2021.672370. ISSN 2296-858X.
  12. Stanculescu, Dominic; Larsson, Lars; Bergquist, Jonas (January 28, 2021). "Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Medicine. 8: 628029. doi:10.3389/fmed.2021.628029. ISSN 2296-858X. PMC 7876311. PMID 33585528.
  13. Bynke, Annie; Julin, Per; Gottfries, Carl-Gerhard; Heidecke, Harald; Scheibenbogen, Carmen; Bergquist, Jonas (August 1, 2020). "Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts". Brain, Behavior, & Immunity - Health. 7: 100107. doi:10.1016/j.bbih.2020.100107. ISSN 2666-3546.
  14. Schutzer, Steven E; Angel, Thomas E.; Liu, Tao; Schepmoes, Athena A.; Clauss, Therese R.; Adkins, Joshua N.; Camp, David G.; Holland, Bart K.; Bergquist, Jonas; Coyle, Patricia K.; Smith, Richard D.; Fallon, Brian A.; Natelson, Benjamin (2011), "Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome", PLoS ONE, 6 (2), doi:10.1371/journal.pone.0017287

cognition Thought processes, including attention, reasoning, and memory.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

β β / Β. Greek letter beta (symbol), equivalent to "b".

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.